Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
| ▸ | CASP7 | P55210 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19544555 | 0.89 | MEN1 (0.41) | CES2FAAHTSHRMEN1KMT2A | |
| SCHEMBL21440855 | 0.89 | MEN1 (0.41) | CES2FAAHTSHRMEN1KMT2A | |
| SCHEMBL21440826 | 0.89 | MEN1 (0.41) | CES2FAAHTSHRMEN1KMT2A | |
| SCHEMBL12118184 | 0.89 | MEN1 (0.41) | CES2FAAHTSHRMEN1KMT2A | |
| SCHEMBL12641023 | 0.89 | MEN1 (0.41) | CES2FAAHTSHRMEN1KMT2A | |
| SCHEMBL15942666 | 0.89 | CES2 (0.40) | CES2FAAHTSHRMEN1KMT2A | |
| SCHEMBL21501522 | 0.88 | CES2 (0.41) | CES2FAAHHSD17B10TSHRMEN1 | |
| SCHEMBL26376485 | 0.86 | CES2 (0.44) | CES2FAAHTSHRMEN1KMT2A | |
| SCHEMBL13040233 | 0.86 | MEN1 (0.41) | CES2FAAHTSHRMEN1KMT2A | |
| SCHEMBL7006602 | 0.86 | MEN1 (0.41) | CES2FAAHTSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160289257-A1 | GLYCOMIMETIC COMPOUNDS AND METHODS TO INHIBIT INFECTION BY HIV | GLYCOMIMETICS INC (US) | 2016-10-06 | — | — | US | disclosed |
| US-20150051164-A1 | PAN-SELECTIN INHIBITOR WITH ENHANCED PHARMACOKINETIC ACTIVITY | GLYCOMIMETICS INC (US) | 2015-02-19 | — | — | US | disclosed |
| US-8895510-B2 | Pan-selectin inhibitor with enhanced pharmacokinetic activity | GLYCOMIMETICS, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-8895510-B2 | Pan-selectin inhibitor with enhanced pharmacokinetic activity | GLYCOMIMETICS, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-20140073594-A1 | GLYCOMIMETIC COMPOUNDS AND METHODS TO INHIBIT INFECTION BY HIV | GLYCOMIMETICS, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20130261070-A1 | ANTI-EPILEPTOGENIC AGENTS | GLYCOMIMETICS, INC. | 2013-10-03 | — | — | US | disclosed |
| US-8518896-B2 | Treatment of cancers of the blood using selected glycomimetic compounds | GLYCOMIMETICS, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518896-B2 | Treatment of cancers of the blood using selected glycomimetic compounds | GLYCOMIMETICS, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| EP-2318015-B1 | TREATMENT OF CANCERS OF THE BLOOD USING SELECTED GLYCOMIMETIC COMPOUNDS | GLYCOMIMETICS INC (US) | 2013-08-07 | — | — | EP | disclosed |
| US-20130184229-A1 | HETEROBIFUNCTIONAL INHIBITORS OF E-SELECTINS AND CXCR4 CHEMOKINE RECEPTORS | GLYCOMIMETICS, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| WO-2011127179-A1 | GLYCOMIMETIC COMPOUNDS AND METHODS TO INHIBIT INFECTION BY HIV | GLYCOMIMETICS, INC. (US) | 2011-10-13 | — | — | WO | disclosed |
| WO-2010126888-A1 | HETEROBIFUNCTIONAL INHIBITORS OF E-SELECTINS AND CXCR4 CHEMOKINE RECEPTORS | GLYCOMIMETICS, INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| US-20100279965-A1 | HETEROBIFUNCTIONAL INHIBITORS OF E-SELECTINS AND CXCR4 CHEMOKINE RECEPTORS | GLYCOMIMETICS, INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100279965-A1 | HETEROBIFUNCTIONAL INHIBITORS OF E-SELECTINS AND CXCR4 CHEMOKINE RECEPTORS | GLYCOMIMETICS, INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-20090312278-A1 | TREATMENT OF CANCERS OF THE BLOOD USING SELECTED GLYCOMIMETIC COMPOUNDS | GLYCOMIMETICS , INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090312278-A1 | TREATMENT OF CANCERS OF THE BLOOD USING SELECTED GLYCOMIMETIC COMPOUNDS | GLYCOMIMETICS , INC. (US) | 2009-12-17 | — | — | US | disclosed |
| WO-2009152245-A1 | TREATMENT OF CANCERS OF THE BLOOD USING SELECTED GLYCOMIMETIC COMPOUNDS | GLYCOMIMETICS, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009126556-A1 | PAN-SELECTIN INHIBITOR WITH ENHANCED PHARMACOKINETIC ACTIVITY | GLYCOMIMETICS, INC. (US) | 2009-10-15 | — | — | WO | disclosed |
| US-20090253646-A1 | PAN-SELECTIN INHIBITOR WITH ENHANCED PHARMACOKINETIC ACTIVITY | GLYCOMIMETICS, INC. (US) | 2009-10-08 | — | — | US | disclosed |
| US-20090253646-A1 | PAN-SELECTIN INHIBITOR WITH ENHANCED PHARMACOKINETIC ACTIVITY | GLYCOMIMETICS, INC. (US) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184229-A1 | HETEROBIFUNCTIONAL INHIBITORS OF E-SELECTINS AND CXCR4 CHEMOKINE RECEPTORS | CXCL12, CXCR4, SELE | CES2 1236/4885FAAH 3597/4885HSD17B10 3862/4885 |
| US-20090253646-A1 | PAN-SELECTIN INHIBITOR WITH ENHANCED PHARMACOKINETIC ACTIVITY | SELPLG, SELP, SELE | CES2 843/4885FAAH 4207/4885HSD17B10 3051/4885 |
| US-20160289257-A1 | GLYCOMIMETIC COMPOUNDS AND METHODS TO INHIBIT INFECTION BY HIV | SIGLEC9, FUT5, FUT6 | CES2 897/4885FAAH 4283/4885HSD17B10 2037/4885 |
| US-20090312278-A1 | TREATMENT OF CANCERS OF THE BLOOD USING SELECTED GLYCOMIMETIC COMPOUNDS | BPGM, CD44, SIGLEC7 | CES2 2579/4885FAAH 4365/4885HSD17B10 2891/4885 |
| US-20100279965-A1 | HETEROBIFUNCTIONAL INHIBITORS OF E-SELECTINS AND CXCR4 CHEMOKINE RECEPTORS | CXCL12, CXCR4, SELE | CES2 1236/4885FAAH 3597/4885HSD17B10 3862/4885 |
| US-20150051164-A1 | PAN-SELECTIN INHIBITOR WITH ENHANCED PHARMACOKINETIC ACTIVITY | SELPLG, SELP, SELE | CES2 843/4885FAAH 4207/4885HSD17B10 3051/4885 |
| US-20130261070-A1 | ANTI-EPILEPTOGENIC AGENTS | GAP43, PYGB, NLN | CES2 301/4885FAAH 810/4885HSD17B10 1041/4885 |
| US-20140073594-A1 | GLYCOMIMETIC COMPOUNDS AND METHODS TO INHIBIT INFECTION BY HIV | SIGLEC9, FUT5, FUT6 | CES2 897/4885FAAH 4283/4885HSD17B10 2037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.